Upcoming FDA Peptide Meeting Sparks Industry Debate

Health and Human Services Secretary Robert F. Kennedy Jr.'s newly reformed Pharmacy Compounding Advisory Committee is set to meet this week to consider adding more peptides to the list of substances that compounding pharmacies can legally produce. The meeting has put the pharmaceutical industry on edge, as observers are divided over whether peptides—which Kennedy has publicly stated he is a 'big fan of'—should be regulated as pharmaceuticals. The debate centers on balancing patient access to compounded peptides with safety and efficacy concerns typically associated with FDA-approved drugs. The outcome could significantly impact the compounding pharmacy sector and the broader peptide market.